ASH 2015 Complete Coverage

Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLL

Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLL

For patients with relapsed/refractory CLL, the addition of idelalisib to bendamustine and rituximab can prove more beneficial than the latter two drugs alone, recent study data suggest.

Study Details Economic Burden of Relapsed/Refractory Multiple Myeloma

Study Details Economic Burden of Relapsed/Refractory Multiple Myeloma

A recent study examined the direct and indirect costs for patients with relapsed or refractory multiple myeloma.

Pretransplant Myeloablative Regimens Confirmed Standard of Care for MDS, AML

Pretransplant Myeloablative Regimens Confirmed Standard of Care for MDS, AML

Results of a phase 3 randomized trial support high intensity conditioning with myeloablative regimens prior to allogeneic stem cell transplantation as standard of care for patients with acute myeloid leukemia.

Venetoclax Induces Deep Remissions in Ultra-High Risk Relapsed/Refractory CLL with 17p Deletion

Venetoclax Induces Deep Remissions in Ultra-High Risk Relapsed/Refractory CLL with 17p Deletion

Treatment with venetoclax monotherapy may be a viable option for some high-risk patients with relapsed/refractory chronic lymphocytic leukemia.

Among Medicare Beneficiaries with MDS, No Association Between Costs of Care, Overall Survival

Among Medicare Beneficiaries with MDS, No Association Between Costs of Care, Overall Survival

Overall survival rates for Medicare beneficiaries with myelodysplastic syndrome (MDS) showed little difference related to disease-related costs, according to data presented at the 2015 ASH Annual Meeting in Florida.

Negative PET Scan Post-ABVD: No Need for RT in Advanced Stage Classical Hodgkin Lymphoma

Negative PET Scan Post-ABVD: No Need for RT in Advanced Stage Classical Hodgkin Lymphoma

A PET-guided approach may reduce the need for additional radiotherapy in some patients with advanced classical Hodgkin lymphoma.

CAR T cells Can Have Powerful Activity in Multiple Myeloma

CAR T cells Can Have Powerful Activity in Multiple Myeloma

In the first clinical trial of an anti-B-cell maturation antigen chimeric antigen receptor (CAR-BCMA), a strong anti-myeloma response was observed.

More Sustainable Pricing Needed for Oral Treatments for Chronic Lymphocytic Leukemia

More Sustainable Pricing Needed for Oral Treatments for Chronic Lymphocytic Leukemia

The high cost of for first-line oral targeted therapies for chronic lymphocytic leukemia needs to be addressed, based on model data examining CLL prevalence and patient affordability.

PET Can Guide Subsequent Treatment in Advanced Stage Hodgkin Lymphoma

PET Can Guide Subsequent Treatment in Advanced Stage Hodgkin Lymphoma

PET deemed safe for use after two cycles of BEACOPPesc chemotherapy for advanced stage Hodgkin lymphoma, according to a recent study.

COG: Immunophenotypic Expression Profiles Can Help Predict Outcome in AML

COG: Immunophenotypic Expression Profiles Can Help Predict Outcome in AML

Immunophenotypic expression profiles can provide a tool to discriminate cohorts of young patients with acute myeloid leukemia (AML) that have a high relapse probability.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs